Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2001
03/22/2001WO2001019369A1 Use of thienopyrimidines
03/22/2001WO2001019368A1 Quinolinone derivative preparations and process for producing the same
03/22/2001WO2001019367A1 Optically active isomers of ketotifen and therapeutically active metabolites thereof
03/22/2001WO2001019366A1 Topical treatment for prevention of ocular infections
03/22/2001WO2001019365A1 Pharmaceutical and/or cosmetical compositions
03/22/2001WO2001019364A1 A method for optimizing pupil size using alpha antagonist
03/22/2001WO2001019363A1 Directly compressible, ultra fine acetaminophen compositions and process for producing same
03/22/2001WO2001019362A2 Formulations for treating or preventing mucositis
03/22/2001WO2001019361A2 Therapeutic uses of polymers and oligomers comprising gamma-hydroxybutyrate
03/22/2001WO2001019360A2 Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
03/22/2001WO2001019359A2 Medicaments containing pantothenic acid for the treatment of inflammatory joint disease
03/22/2001WO2001019358A2 Use dexrazoxane for treating psoriasis
03/22/2001WO2001019356A2 High lipid diet
03/22/2001WO2001019355A2 Novel dicarboxylic acid derivatives with pharmaceutical properties
03/22/2001WO2001019354A2 Composition for ivf
03/22/2001WO2001019353A2 Agents for treating human diseases, especially for treating tumors such as colonic cancers and melanomas or for regenerating tissue and promoting hair growth
03/22/2001WO2001019352A1 Transdermal administration of n-(2,5-disubstituted phenyl)-n'-(3-substituted phenyl)-n'-methyl guanidines
03/22/2001WO2001019351A1 Plastic films, especially for use in a dermal or transdermal therapeutic system
03/22/2001WO2001019350A1 Controlled release formulation for administration of an anti-inflammatory naphthalene derivative
03/22/2001WO2001019349A2 Extended release formulation of etodolac
03/22/2001WO2001019348A1 Stabilization of enalapril maleate with maleic acid
03/22/2001WO2001019347A1 Vascular coating composition
03/22/2001WO2001019346A1 Delayed release nabumetone formulation
03/22/2001WO2001019342A2 Pharmaceutical formulation of fluticasone propionate
03/22/2001WO2001019341A1 Method for modulating the metabolism of nitrogen oxides, compositions therefor (and variants) and method for acting on a patient's organism necessitating the metabolism of nitrogen oxides to be corrected
03/22/2001WO2001019340A1 Dispersion formulations containing lipase inhibitors
03/22/2001WO2001019339A1 Formulations for parenteral use of estramustine phosphate and sulfoalkyl ether cyclodextrins
03/22/2001WO2001019338A1 Formulations for parenteral use of estramustine phosphate with improved pharmacological properties
03/22/2001WO2001019337A2 Dosage forms and methods for providing effective reboxetine therapy with once-a-day dosing
03/22/2001WO2001019336A1 Galenic formulations fast disintegrating in the mouth and method for preparing same
03/22/2001WO2001019334A2 Pharmaceutical solutions of levosimendan
03/22/2001WO2001019323A1 Tyrosinase activity inhibitors and cosmetics
03/22/2001WO2001019322A2 Use of csaids in rhinovirus infection
03/22/2001WO2001019321A2 Methods for treating neuropathic pain using hetreoarylmethanesulfonamides
03/22/2001WO2001019320A2 Phospholipid prodrugs of anti-proliferative drugs
03/22/2001WO2001019204A1 Breath freshening comestible product
03/22/2001WO2001019191A1 Method for the production of polyvinylpyrrolidone-iodine in an aqueous solution
03/22/2001WO2001019161A2 ANTISENSE MODULATION OF TRANSFORMING GROWTH FACTOR-β EXPRESSION
03/22/2001WO2001019158A2 An anti-oxidant preparation based on plant extracts for the treatment of circulation and adiposity problems
03/22/2001WO2001008661A3 Opioid sustained-released formulation
03/22/2001WO2001005435A3 Antisense therapy for hormone-regulated tumors
03/22/2001WO2001000188A3 Tetrahydroquinolinyl-6-methyldihydrothiadiazinone derivatives and their use for preventing and/or treating anaemia
03/22/2001WO2000078341A8 A method for the prophylaxis and/or treatment of medical disorders
03/22/2001WO2000074629A3 Composition for implementing a cytotoxic, in particular an antitumoral or antiviral, treatment in a mammal
03/22/2001WO2000073323A3 Adam polynucleotides and polypeptides
03/22/2001WO2000069862A3 Hemisynthetic method and intermediates thereof
03/22/2001WO2000069421A3 Transdermal therapeutic system (tts) containing tolterodine
03/22/2001WO2000069255A8 Anti-inflammatory therapy for inflammatory mediated infection
03/22/2001WO2000068229A3 (s)-benzoquinolizine carboxylic acids and their use as antibacterial agents
03/22/2001WO2000066096A3 Use of antiepileptics for treating respiratory disorders, in particular asthmatic disorders
03/22/2001WO2000061134A8 Antimicrobial agents
03/22/2001WO2000059899A8 Novel lipoic acid derivatives, their preparation, and pharmaceutical compositions containing them
03/22/2001WO2000055155A3 Heterocyclic compounds as adenosine deaminase inhibitors
03/22/2001WO2000040576A3 Thiopyran compounds as inhibitors of mmp
03/22/2001WO2000035469A9 hCG THERAPY FOR THE TREATMENT OF BREAST CANCER
03/22/2001WO2000035435A9 Use of a mek inhibitor for preventing transplant rejection
03/22/2001WO2000032177A3 Use of 17-ketosteroids in the treatment of hepatitis c virus and other togavirus infections
03/22/2001WO2000001376A3 Pharmaceutical compositions and their uses for treatment of demyelinating disorders
03/22/2001WO1999067809A9 Compositions and methods for inhibiting bone resorption
03/22/2001WO1999063936A8 Novel therapeutic agents that modulate endothelin receptors
03/22/2001WO1999058678A9 Antibodies to dendritic cells and human dendritic cell populations and uses thereof
03/22/2001WO1999051240A8 Acylbenzoxazines for enhancing synaptic response(s)
03/22/2001DE19944604A1 Aminderivate Amine derivatives
03/22/2001DE19944464A1 Verfahren zur Herstellung von Polyvinylpyrrolidon-lod in wässriger Lösung A process for preparing polyvinylpyrrolidone-iodine in aqueous solution
03/22/2001DE19944404A1 Mittel zur Therapie von menschlichen Erkrankungen, insbesondere für die Therapie von Tumoren wie Kolonkarzinomen und Melanomen oder zur Geweberegeneration und Förderung des Haarwuchses Means for therapy of human disease, in particular for the treatment of tumors such as colon carcinoma and melanoma, or for tissue regeneration and promote hair growth
03/22/2001DE19944332A1 Antikonvulsiv und anxiolytisch wirkende 4-Amino-1-aryl-1,5-dihydro-pyrrol-2-one und Verfahren zu deren Herstellung Anticonvulsant and anxiolytic 4-amino-1-aryl-1,5-dihydro-pyrrol-2-one and processes for their preparation
03/22/2001DE19944137A1 O/W-Emulsionen mit einem Gehalt an einem oder mehreren Biochinonen und einem erhöhten Gehalt an Glycerin O / W emulsions with a content of one or more bioquinones and an elevated content of glycerol
03/22/2001DE10036855A1 Neue kristalline Form von 6-Hydroxy-3-(4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophenhydrochlorid New crystalline form of 6-hydroxy-3- (4- [2- (piperidin-1-yl) ethoxy] phenoxy) -2- (4-methoxyphenyl) benzo [b] thiophene hydrochloride
03/22/2001CA2672722A1 Methods of preparing substituted tetracyclines with transition metal-based chemistries
03/22/2001CA2393896A1 Pteridinones as kinase inhibitors
03/22/2001CA2388383A1 Agents for treating human diseases, especially for treating tumors such as colonic cancers and melanomas or for regenerating tissue and promoting hair growth
03/22/2001CA2387123A1 Use of thienopyrimidines
03/22/2001CA2386525A1 Method for modulating the metabolism of nitrogen oxides, compositions therefor (and variants) and method for acting on a patient's organism necessitating the metabolism of nitrogen oxides to be corrected
03/22/2001CA2385769A1 Kinase inhibitors as therapeutic agents
03/22/2001CA2385747A1 Pyrazolopyrimidines as therapeutic agents
03/22/2001CA2385722A1 Use of csaids in rhinovirus infection
03/22/2001CA2385589A1 Inhibitors of factor xa
03/22/2001CA2385065A1 Formulations for parenteral use of estramustine phosphate and sulfoalkyl ether cyclodextrins
03/22/2001CA2385063A1 Formulations for parenteral use of estramustine phosphate with improved pharmacological properties
03/22/2001CA2384991A1 Use of mullerian inhibiting substance for treating excess androgen states
03/22/2001CA2384987A1 Nucleic acids encoding polyepitope polypeptides
03/22/2001CA2384986A1 Transdermal administration of n-(2,5-disubstituted phenyl)-n'-(3-substituted phenyl)-n'-methyl guanidines
03/22/2001CA2384974A1 Compounds and pharmaceutical compositions as cathepsin s inhibitors
03/22/2001CA2384898A1 Antiviral agents
03/22/2001CA2384861A1 Combination of c1-inh and lung surfactant for the treatment of respiratory disorders
03/22/2001CA2384783A1 Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
03/22/2001CA2384782A1 Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
03/22/2001CA2384763A1 Tryptase inhibitors
03/22/2001CA2384749A1 Novel human proteins, polynucleotides encoding them and methods of using the same
03/22/2001CA2384733A1 Methods and compositions utilizing rad51
03/22/2001CA2384726A1 Formulations for parenteral use of estramustine phosphate and amino acids
03/22/2001CA2384685A1 Use dexrazoxane for treating psoriasis
03/22/2001CA2384656A1 New active marine alkaloids
03/22/2001CA2384646A1 Taxane prodrugs
03/22/2001CA2384645A1 Amphiphilic prodrugs
03/22/2001CA2384324A1 Proteins associated with cell differentiation
03/22/2001CA2384247A1 Azacycloalkanone serine protease inhibitors
03/22/2001CA2384246A1 Glucosamine and egg reducing inflammation
03/22/2001CA2384081A1 Recombinant microorganisms expressing an oligosaccharide receptor mimic
03/22/2001CA2383988A1 Indole-containing and combretastatin-related anti-mitotic and anti-tubulin polymerization agents